Company Products (7) Financing (1) Management (23)
 
ADETHERAPEUTICS INC
BIOTECHGATE BY VENTURE VALUATION
Latest up-date: 11 Jun 2014
GENERAL INFORMATION
G
P
T
F
M
D
 
2-410 Downey Rd
Innovation Place Research Park
S7N4N1 Saskatoon
Canada, Saskatchewan
Contact person Mr. Sanj Singh, President & CEO
Company main phone +1 (306) 2615189
E-mail [available with subscription]
Website www.adetherapeutics.com
 
Founded (year) 2006
Source of foundation Independent foundation
   
Corporate description / mission
AdeTherapeutics is a privately-held clinical-stage drug development company developing products that deal with complications related to surgery, such as tissue fibrosis.
State of ownership Private / independent
Headquarters Yes
CATEGORIZATION
G
P
T
F
M
D
 
Main sector Biotechnology - Therapeutics and Diagnostics
Subsector(s)
  • Peptides
Primary therapeutic area(s)
  • Skin and subcutaneous tissue
  • Musculoskeletal system and connective tissue
  • Genitourinary system
  • External causes of morbidity and mortality
 
Business model
  • In-licensing
  • Out-licensing
  • R&D
Customer segments
  • Large biotech & big pharma
  • Hospitals
SUMMARY PRODUCTS / SERVICES / TECHNOLOGIES
G
P
T
F
M
D
 
No. of Biotech Products Pre-clinical Phase I Phase II Phase III On the market
  3 1 1 n/a n/a
No. of Medtech Products In development       On the market
  2       n/a
Description of products
Lead indication is in the gyne/general surgical market for the prevention of adhesion formation. The product is a therapeutic using a highly safe peptide which can be used in all types of surgeries and easily delivered in open and scope surgeries. Ade-SPN is a product created through a joint collaboration with DSM Biomedical. It prevents the formation of epdiural fibrosis and assists with the associated pain following spinal surgery.
Special IP situation
EU, Japan, Australia-issued
USA, Canada-pending
Technology used
Evitar is used to correct the imbalance in the system brought on by hypoxia due to surgical injury which triggers the cascading activation of many pro-inflammatory pathways (including TGF-Beta) that promote adhesion or fibrosis development. The administration of Evitar acts a metabolic fuel for cells in stressed conditions and restores proper function of mesothelial cells and the resident macrophages and fibroblasts, promoting fibrotic free resolution or healing. Restoring homeostasis within the first few critical hours after injury helps to inhibit the inflammatory pathways and promotes normal regeneration.
COLLABORATIONS, CLIENTS & MARKETS
G
P
T
F
M
D
 
Partnering strategy / collaborations
Looking to exit after phase II trials...three additional products uses same technology platform and different formulations for separate indications
KEY
G
General profile
P
Products
T
Technologies
F
Financing rounds
M
Management
D
Deals
 
 
Click here to update this profile >>
© 2014 Venture Valuation  |  Impressum  |  Terms of Use & Privacy Policy  |  Print